Immuno-oncology Crossbridge Bio raises seed financing to advance dual-payload ADCs for cancer Nov. 6, 2024 Crossbridge Bio Inc. has closed a $10 million seed financing to support its development of dual-payload antibody-drug conjugates (ADCs) for cancer. Read More
